S&P 500   4,286.59 (+0.10%)
DOW   33,652.91 (-0.33%)
QQQ   356.22 (+0.44%)
AAPL   183.33 (+1.32%)
MSFT   337.67 (+0.68%)
META   273.05 (+0.16%)
GOOGL   126.73 (+1.65%)
AMZN   124.73 (+0.39%)
TSLA   217.90 (+1.84%)
NVDA   389.90 (-0.86%)
NIO   7.74 (+2.38%)
BABA   83.98 (-0.34%)
AMD   118.22 (+0.31%)
T   15.32 (+0.72%)
F   12.63 (+1.94%)
MU   68.00 (-1.69%)
CGC   0.79 (-4.50%)
GE   104.62 (-1.12%)
DIS   89.83 (-1.04%)
AMC   4.61 (+1.32%)
PFE   38.78 (+1.09%)
PYPL   64.40 (+0.69%)
NFLX   409.97 (+2.37%)
S&P 500   4,286.59 (+0.10%)
DOW   33,652.91 (-0.33%)
QQQ   356.22 (+0.44%)
AAPL   183.33 (+1.32%)
MSFT   337.67 (+0.68%)
META   273.05 (+0.16%)
GOOGL   126.73 (+1.65%)
AMZN   124.73 (+0.39%)
TSLA   217.90 (+1.84%)
NVDA   389.90 (-0.86%)
NIO   7.74 (+2.38%)
BABA   83.98 (-0.34%)
AMD   118.22 (+0.31%)
T   15.32 (+0.72%)
F   12.63 (+1.94%)
MU   68.00 (-1.69%)
CGC   0.79 (-4.50%)
GE   104.62 (-1.12%)
DIS   89.83 (-1.04%)
AMC   4.61 (+1.32%)
PFE   38.78 (+1.09%)
PYPL   64.40 (+0.69%)
NFLX   409.97 (+2.37%)
S&P 500   4,286.59 (+0.10%)
DOW   33,652.91 (-0.33%)
QQQ   356.22 (+0.44%)
AAPL   183.33 (+1.32%)
MSFT   337.67 (+0.68%)
META   273.05 (+0.16%)
GOOGL   126.73 (+1.65%)
AMZN   124.73 (+0.39%)
TSLA   217.90 (+1.84%)
NVDA   389.90 (-0.86%)
NIO   7.74 (+2.38%)
BABA   83.98 (-0.34%)
AMD   118.22 (+0.31%)
T   15.32 (+0.72%)
F   12.63 (+1.94%)
MU   68.00 (-1.69%)
CGC   0.79 (-4.50%)
GE   104.62 (-1.12%)
DIS   89.83 (-1.04%)
AMC   4.61 (+1.32%)
PFE   38.78 (+1.09%)
PYPL   64.40 (+0.69%)
NFLX   409.97 (+2.37%)
S&P 500   4,286.59 (+0.10%)
DOW   33,652.91 (-0.33%)
QQQ   356.22 (+0.44%)
AAPL   183.33 (+1.32%)
MSFT   337.67 (+0.68%)
META   273.05 (+0.16%)
GOOGL   126.73 (+1.65%)
AMZN   124.73 (+0.39%)
TSLA   217.90 (+1.84%)
NVDA   389.90 (-0.86%)
NIO   7.74 (+2.38%)
BABA   83.98 (-0.34%)
AMD   118.22 (+0.31%)
T   15.32 (+0.72%)
F   12.63 (+1.94%)
MU   68.00 (-1.69%)
CGC   0.79 (-4.50%)
GE   104.62 (-1.12%)
DIS   89.83 (-1.04%)
AMC   4.61 (+1.32%)
PFE   38.78 (+1.09%)
PYPL   64.40 (+0.69%)
NFLX   409.97 (+2.37%)
NASDAQ:CRME

Cardiome Pharma (CRME) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$2.30
$2.45
50-Day Range
N/A
52-Week Range
$1.29
$4.84
Volume
90,444 shs
Average Volume
135,322 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CRME stock logo

About Cardiome Pharma (NASDAQ:CRME) Stock

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

Receive CRME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiome Pharma and its competitors with MarketBeat's FREE daily newsletter.

CRME Stock News Headlines

Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium
The soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.
AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
Jenny Sundqvist new CEO of InDex Pharmaceuticals
See More Headlines


CRME Company Calendar

Last Earnings
5/15/2018
Today
6/05/2023

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRME
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A

Key Executives

  • Dr. William L. Hunter (Age 55)
    Pres, CEO & Director
  • Ms. Sheila M. Grant MBA
    Chief Operating Officer
  • Mr. David D. McMasters (Age 59)
    Gen. Counsel
  • Mr. Hugues Sachot
    Chief Commercial Officer
  • Mr. Justin A. Renz (Age 46)
    Chief Financial Officer













CRME Stock - Frequently Asked Questions

How were Cardiome Pharma's earnings last quarter?

Cardiome Pharma Corp (NASDAQ:CRME) issued its earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.02. The biopharmaceutical company had revenue of $6.54 million for the quarter, compared to the consensus estimate of $7.34 million.

What other stocks do shareholders of Cardiome Pharma own?
What is Cardiome Pharma's stock symbol?

Cardiome Pharma trades on the NASDAQ under the ticker symbol "CRME."

What is Cardiome Pharma's stock price today?

One share of CRME stock can currently be purchased for approximately $2.33.

How can I contact Cardiome Pharma?

Cardiome Pharma's mailing address is 1441 Creekside Drive 6th Floor, Vancouver A1, V6J 4S7. The official website for the company is www.cardiome.com. The biopharmaceutical company can be reached via phone at 604-677-6905 or via email at ir@cardiome.com.

This page (NASDAQ:CRME) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -